<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>PolyQ - SCA1</title>
  <link rel="shortcut icon" href="../../Images/image1.ico">
  <link rel="stylesheet" href="style_2.css">
  <link rel="stylesheet" href="highlight-js/highlightjs.css">
  <link rel="stylesheet" href="ScrollSpy.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.1.1/css/all.min.css" integrity="sha512-KfkfwYDsLkIlwQp6LFnl8zNdLGxu9YAA1QvwINks4PhcElQSvqcyVLLD9aMhXd13uQjoXtEKNosOWaZqXgel0g==" crossorigin="anonymous" referrerpolicy="no-referrer" />
  <link rel="stylesheet" href="int-image.css">
</head>
<body>
  <script src="ScrollSpy.min.js"></script>
  <script src="highlight-js/highlight.pack.js"></script>
    <header>
      <a href="https://abcri.pt/"><img class="abcri-logo" src="../../Images/Logo_ABCRI.png"></a>
      <a><img class="mngt-logo" src="../../Images/Logo_MNGT.png"></a>
      <h1> <strong>An ABC Research Institute polyglutamine disease database</strong></h1>
    </header>
  <nav>
    <img class="poly-logo" src="../../Images/logo-plyq.png"/>
    <ul>
      <li><a href="../hd">HD</a></li>
      <li><a href="../drpla">DRPLA</a></li>
      <li><a href="../sbma">SBMA</a></li>
    </ul>
      <div class="dropdown">
        <button onclick="myFunction()" class="dropbtn">More <i class="fa-solid fa-caret-down"></i></button>
        <div class="dropdown-content" id="myDropdown">
          <a href="../sca2">SCA2</a>
          <a href="../sca3">SCA3</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca7">SCA7</a>
          <a href="../sca17">SCA17</a>
        </div>
      </div>
      <div class="dropdown-little">
        <button onclick="myFunctionLittle()" class="dropbtn-little">Other Diseases &nbsp <i class="fa-solid fa-turn-down"></i></button>
        <div class="dropdown-content-little" id="myDropdownLittle">
          <a href="../hd">HD</a>
          <a href="../drpla">DRPLA</a>
          <a href="../sbma">SBMA</a>
          <a href="../sca2">SCA2</a>
          <a href="../sca3">SCA3</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca7">SCA7</a>
          <a href="../sca17">SCA17</a>
        </div>
      </div>
    <a href="../../home" class="return-button"><i class="fa-solid fa-house"></i> Return to Home page </a>
    <a href="../../home" class="return-little"><i class="fa-solid fa-house"></i> Home </a>
  </nav>
  <main>
    <div class="aside-bar-left">
      <h3> Page navigation</h3>
      <div id="indicator"></div>
    </div>
    <div class="text">
    <h1><a href="./"><i class="fa-solid fa-caret-right"></i> &nbspSpinocerebellar Ataxia 1</a></h1>
    <section class="scrollspy" spy-title="Introduction">
      <div class="intro-section">
        <h2> Introduction </h2>
        <p>
          Spinocerebellar ataxia type 1 (SCA1) is a condition characterized by progressive problems with movement. People with this condition initially experience problems with coordination and balance (ataxia).
        </p>
        <p>
          SCA1 is an autosomal dominant disease, meaning that at least one parent must have the disease for the children to inherit it, and that the odds of any given child inheriting SCA 1, regardless of gender or other phenotypes, is 50% if the affected parent is heterozygous.
        </p>
        <p>
          Signs and symptoms of the disorder typically begin in early adulthood but can appear anytime from childhood to late adulthood.
        </p>
        <p>
          People with SCA1 typically survive 10 to 20 years after symptoms first appear.
        </p>
      </div>
    </section>
    <section class="scrollspy" spy-title="First described">
      <div class="firstd-section">
      <h2> First Described</h2>
      <p>
        SCA1 research began in the last half of the nineteenth century with genetic applications. Between 1863 and 1877, Friedreich described a recessive form of hereditary ataxia that today bears his name, but in 1893, Pierre Marie noticed a form of ataxia in four families with a clinical picture distinct from that described by Friedreich <span class="refbig"><a href="#ref-one">[1]</a></span><span class="reflittle"><a href="#ref-one-little">[1]</a></span>. Ataxias recognized by Marie have evolved into the autosomal dominant ataxias or spinocerebellar ataxias (SCAs).</p>
     </div>
    </section>
    <section class="scrollspy" spy-title="Epidemiology">
      <div class="epi-section">
        <h2> Epidemiology</h2>
        <p>
          Worldwide, one to two individuals in 100,000 develop SCA1 with significant geographical and ethnic variations.
        </p>
        <input type="checkbox" id="zoomCheck">
        <label for="zoomCheck">
          <img src="../../Images/original images/SCA1/SCA1_prevalence.png">
        </label>
        <figcaption> <strong>Figure 1.</strong> World chart of SCA1 epidemiology based on its prevalence within the autosomal dominant ataxias <span class="refbig"><a href="#ref-two">[2]</a></span><span class="reflittle"><a href="#ref-two-little">[2]</a></span>.</figcaption>
        <a class="download-image" href="../../Images/original images/SCA1/SCA1_prevalence.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Causative gene">
        <div class="gene-section">
          <h2>Causative gene</h2>
          <p>
            ATXN1 gene spans 450 kb of genomic DNA and is organized into 9 exons <span class="refbig"><a href="#ref-three">[3]</a></span><span class="reflittle"><a href="#ref-three-little">[3]</a></span>. The first 7 fall in the 5-prime untranslated region, whereas the last 2 contain the coding region (21.982 nt) (<a href="#gene-image1">Figure 2</a>). There is an increased ammount of CAG repeats in exon 8 when disease is present. CAG repeats are usually interrupted by CAT trinucleotides
            <span class="refbig"><a href="#ref-four">[4]</a></span><span class="reflittle"><a href="#ref-four-little">[4]</a></span>. CATs are thought to be involved in the stability of the trinucleotide stretch during DNA replication <span class="refbig"><a href="#ref-four">[4]</a></span><span class="reflittle"><a href="#ref-four-little">[4]</a>
            </span>.
          </p>
          <p>
            Normal SCA1 alleles contain from 6 to 43 CAG repeats with those greater than 21 being interrupted with 1 – 3 CAT trinucleotides. Disease alleles, on the other hand, are pure CAG tracts ranging from 44 (39 if uninterrupted) to 82 units. Such interruptions are found in all the longer unaffected alleles. In contrast, all affected alleles are pure CAG tracts   <span class="refbig"><a href="#ref-five">[5]</a></span><span class="reflittle"><a href="#ref-five-little">[5]</a></span>. The presence of repeat interruptions particularly in the longer wild type alleles lead to the possibility that the CAT interruptions have an important function of maintaining stability of normal alleles (<a href="#gene-image1">Figure 2</a>).
          </p>
          <p>
            ATXN1 gene codes for ataxin-1 and is in the short arm of chromosome 6 (<a href="#gene-image2">Figure 3</a>), according to NCBI (from <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000332">RefSeq NM_000332.4</a>).
          </p>
          <div class="image-one">
            <img id="gene-image1" src="../../Images/original images/SCA1/ATXN1.png" title="AR gene">
            <figcaption> <strong>Figure 2:</strong> ATXN1 gene with ranges of the CAG repeats necessary for disease and range in healthy individuals along with information about the total coding exons, chromosome location and size in DNA bases. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA1/ATXN1.png" download> [Fullsize image] </a>
          </div>
          <div class="image-two">
            <img id="gene-image2" src="../../Images/original images/SCA1/chromosome.png" title="AR gene chromosomal location">
            <figcaption> <strong>Figure 3:</strong> ATXN1 gene chromossomal band localization. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA1/chromosome.png" download> [Fullsize image] </a>
          </div>
        </div>
    </section>
    <section class="scrollspy" spy-title="Codified protein">
      <div class="protein-section">
        <h2>Codified protein: structure, domains, functions and intracellular localization</h2>
        <h3>Structure and domains</h3>
        <p>
          ATXN1 gene codes for ataxin-1. Ataxin-1 has 815 amino acids and a molecular mass of 86923 Da (~87 kDa). Ataxin-1 is a ubiquitous polyglutamine protein expressed primarily in the nucleus.
        </p>
        <p>
          Spinocerebellar ataxia is caused when ataxin-1 is mutated, this is when ataxin-1 has a bigger than normal number of glutamines where the protein can no longer be stable and leads to cellular problems that eventually result in disease.
        </p>
        <p>
           An ataxin-1 protein representation is shown in <a href="#protein-image">Figure 4</a> along with <a href="#table">Table 1</a> with information on its important domain/s (information from <a href="https://www.uniprot.org/">Uniprot.org</a>).
        </p>
        <div class="non-interactive">
          <img id="protein-image" src="../../Images/original images/SCA1/Ataxin-1.png" title="Androgen receptor structure">
          <figcaption> <strong>Figure 4: </strong> Ataxin-1 structure and important domains. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
          <a class="download-image" target="_blank" href="../../Images/original images/SCA1/Ataxin-1.png" download> [Fullsize image] </a>
        </div>
        <div class="table">
        <table style="width:100%" id="table">
          <caption>Table 1. Ataxin-1 important domain</caption>
          <tr>
            <th>Description</th>
            <th>Position</th>
            <th>Length</th>
          </tr>
          <tr>
            <td>AXH</td>
            <td>562-689</td>
            <td>127</td>
          </tr>
        </table>
        <div class="caption-under"> <strong>Table Caption:</strong> Ataxin-1 domain with respective position and length.</div>
        </div>
        <h3>Protein functions and biological role</h3>
        <p>
          Ataxin-1 has important molecular functions regarding transcription:
        </p>
        <ul>
          <li>It binds chromatin (DNA) and functions as a transcriptional repressor.</li>
          <li>It has the ability to bind RNA <span class="refbig"><a href="#ref-six">[6]</a></span><span class="reflittle"><a href="#ref-six-little">[6]</a></span> and to self-associate through certain regions <span class="refbig"><a href="#ref-seven">[7]</a></span><span class="reflittle"><a href="#ref-seven-little">[7].
          </a></span></li>
          <li>RNA processing function <span class="refbig"><a href="#ref-eight">[8]</a></span><span class="reflittle"><a href="#ref-eight-little">[8]</a></span></li>
        </ul>
        <p>
          According to <a href="https://www.uniprot.org/uniprot/P10275">UniProt.org</a> the ATXN1 gene product is involved in various biological processes from early nervous system development to keeping its stability and normal functioning throughout the years. It has important roles in brain development, learning and memory.
        </p>
        <h3> Protein intracellular localization</h3>
        <p>
          Ataxin-1 is widely expressed in the normal human brain and peripheral tissues. It is present in both nucleus and cytoplasm. Within neurons, ATXN1 is predominantly nuclear, with some cytoplasmic ATXN1 found in Purkinje cells and brainstem nuclei <span class="refbig"><a href="#ref-nine">[9]</a></span><span class="reflittle"><a href="#ref-nine-little">[9]
          </a></span>, <span class="refbig"><a href="#ref-ten">[10]</a></span><span class="reflittle"><a href="#ref-ten-little">[10]
          </a></span>.
        </p>
        <div class="interactive-image" id="my-interactive-image">
          <img src="../../Images/cell-scheme.jpg" />
        </div>
        <div class="int-caption"> <strong>Figure 5:</strong> Androgen receptor intracellular localization.<br>(Refresh this element if changed resolutions &nbsp<a href="javascript:void(0)" onclick="window.location.reload();"><i class="fa-solid fa-arrows-rotate"></i></a>&nbsp)</div>
      </div>
    </section>
    <section class="scrollspy" spy-title="Pathophysiology">
      <div class="patho-section">
        <h2> Pathophysiology</h2>
        <p>
          Disease-related expansions have a direct relationship between length and severity/age-of-onset of disease, i.e. longer the longer the glutamine tract the more severe and earlier is the age of onset of disease.
        </p>
        <p>
          The presence of expanded glutamine (Q) repeats in Ataxin-1 impairs ubiquitination and degradation, leading to its accumulation in neurons and subsequent toxicity <span class="refbig"><a href="#ref-eleven">[11]</a></span><span class="reflittle"><a href="#ref-eleven-little">[11]</a></span>. On the other hand, some other studies reported that accumulation in neurons showed no further disease worsening and disease specimens with less or close to none neuronal inclusions still developed disease as cases with accumulation of poly-Q ataxin-1 <span class="refbig"><a href="#ref-twelve">[12]</a></span><span class="reflittle"><a href="#ref-twelve-little">[12]</a></span>, <span class="refbig"><a href="#ref-thirteen">[13]</a></span><span class="reflittle"><a href="#ref-thirteen-little">[11]</a></span>.
        </p>
        <p>
          Biochemical and genetic studies provide evidence that the polyglutamine expansion enhances interactions that are normally regulated by phosphorylation at Ser776 and a subsequent alteration in its interaction with other cellular proteins <span class="refbig"><a href="#ref-thirteen">[13]</a></span><span class="reflittle"><a href="#ref-thirteen-little">[13]</a></span>.
        </p>
        <p>
          S776 phosphorylation confers to Ataxin-1 great stability and enhances protein-protein interactions. Interaction of pS776-Ataxin-1 with 14-3-3 stabilizes the first. The chaperone 14-3-3 bound to pS776-Ataxin-1 protects the latter from degradation which may lead to toxic levels of the protein <span class="refbig"><a href="#ref-fourteen">[14]</a></span><span class="reflittle"><a href="#ref-fourteen-little">[14]</a></span>.
        </p>
        <p>
          SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle. SUMOylation is dependent on nuclear localization and phosphorylation at Ser-776. It is reduced in the presence of an expanded polyglutamine tract <span class="refbig"><a href="#ref-thirteen">[13]</a></span><span class="reflittle"><a href="#ref-thirteen-little">[13]</a></span>, <span class="refbig"><a href="#ref-fifteen">[15]</a></span><span class="reflittle"><a href="#ref-fifteen-little">[15]</a>
          </span>.
        </p>
        <p>
          The ataxin-1 AXH domain allows its homodimerization and interaction with regulators of transcription such as the transcriptional repressor Capicua (Cic). Ataxin-1 and Cic together exist in large protein complexes where mutant ataxin-1 is thought to affect Cic repressor activity. In addition to regulating Cic function, stability of Cic depends on Ataxin-1 binding <span class="refbig"><a href="#ref-fourteen">[14]</a></span><span class="reflittle"><a href="#ref-fourteen-little">[14]</a></span>. Poly-Q ataxin-1 has presented evidence that the interaction with RBM17 (RNA-binding motif protein 17) is enhanced since it seemed RBM17 interacted preferably with polyglutamine-expanded ataxin-1 and its phosphorylated forms.
        </p>
        <p>
          Ataxin-1 toxicity acts through a gain of function mechanism, where mutant Ataxin-1 affects the normal function of an Ataxin-1 binding partner (Cic) and exacerbates its normal gene-repressor function in vivo <span class="refbig"><a href="#ref-sixteen">[16]</a></span><span class="reflittle"><a href="#ref-sixteen-little">[16]</a></span>,
          <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>. Thus, mutant Ataxin-1 also results in Cic loss of function, revealing complexity in Ataxin-1 effects
          <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>.
        </p>
        <img id="patho-img" src="../../Images/original images/SCA1/SCA1.png" title="SCA1 pathogenic mechanisms">
        <div class="caption-patho"> <strong>Figure 6:</strong> SCA1 pathogenesis. A - Aggregation of mutated ataxin-1 inside the cell and nucleus. B - PolyQ ataxin-1 is less ubiquitinated leading to less degradation of this mutated form of the protein. Ataxin-1 with expanded glutamines is also less targeted by SUMO and so it is less SUMOylated affecting cellular stability. C - Interaction of mutated ataxin-1 with chaperones is enhanced resulting in the protection of the first from degradation therefore increasing toxic levels of the mutated protein inside the cell. D - PolyQ ataxin-1 shifts the balance of interactions. Mutated ataxin-1 interacts more with RBM17 and affects Cic function leading to its exacerbated function or loss of function in some cases (* check   <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>).</div>
        <a class="download-image" target="_blank" href="../../Images/original images/SCA1/SCA1.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Clinical manifestations">
      <div class="clinical-section">
        <h2> Clinical manifestations: neuropathology, other signs and symptoms</h2>
        <h3>Neuropathology</h3>
        <p>
          Spinocerebellar ataxia type 1 (SCA1) primarily affects the brainstem, spinocerebellar tracts and cerebellar Purkinje cells.
        </p>
        <p>
          SCA1 has many pathoanatomical findings in various tissues <span class="refbig"><a href="#ref-eightteen">[18]</a></span><span class="reflittle"><a href="#ref-eighteen-little">[18]</a>
          </span>:
        </p>
        <div class="list-neuronal">
        <ul>
          <li>Neuronal loss in the neocortex</li>
          <li>Neuronal loss in the basal forebrain nuclei, basal ganglia, amygdala, hypothalamus and thalamus</li>
          <li>Neuronal loss in the cerebellum</li>
          <li>Neuronal loss in the midbrain</li>
          <li>Neuronal loss in the pons and medulla oblongata</li>
          <li>Neuronal intranuclear inclusion</li>
          <li>Astrogliosis</li>
        </ul>
        </div>
        <h3>Signs and symptoms</h3>
        <div class="list-flex">
          <div class="column-one">
            <div class="column-one-title">
              <strong>Neurological symptoms</strong>
            </div>
          <ul>
            <li>Dysarthria</li>
            <li>Hypermetric saccades</li>
            <li>Ataxia of gait</li>
            <li>Ataxia of stance</li>
          </ul>
          </div>
          <div class="column-two">
            <div class="column-two-title">
              <strong>Other signs and symptoms</strong>
            </div>
          <ul>
            <li>Speech and swallowing difficulties</li>
            <li>Spasticity</li>
            <li>Ophthalmoplegia</li>
            <li>Nystagmus</li>
            <li>Cognitive impairment</li>
          </ul>
          </div>
      </div>
    </div>
    </section>
    <section class="scrollspy" spy-title="References" id="references">
      <div class="reference-section">
        <h2> References </h2>
        <ol>
          <li><a id="ref-one-little" class="articlebottom">H. T. Orr and H. Y. Zoghbi, “SCA1 molecular genetics: a history of a 13 year collaboration against glutamines,” Hum. Mol. Genet., vol. 10, no. 20, pp. 2307–2311, Oct. 2001.</a><br><a href="https://academic.oup.com/hmg/article/10/20/2307/559359">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-two-little" class="articlebottom">P. Opal and T. Ashizawa, “Spinocerebellar Ataxia Type 1,” GeneReviews®, Jun. 2017, Accessed: Mar. 07, 2022. [Online]. Available:</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK1184/">[NCBI Books]</a></li>
          <li><a id="ref-three-little" class="articlebottom">S. Banfi et al., “Identification and characterization of the gene causing type 1 spinocerebellar ataxia,” Nat. Genet. 1994 74, vol. 7, no. 4, pp. 513–520, 1994</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7951322/">[PUBMED]</a><a href="https://www.nature.com/articles/ng0894-513">[Nature]</a></li>
          <li><a id="ref-four-little" class="articlebottom">S. Nethisinghe et al., “PolyQ tract toxicity in SCA1 is length dependent in the absence of CAG repeat interruption,” Front. Cell. Neurosci., vol. 12, p. 200, Jul. 2018.</a><a href="https://www.frontiersin.org/articles/10.3389/fncel.2018.00200/full">[Frontiers - Full Text]</a></li>
          <li><a id="ref-five-little" class="articlebottom">H. T. Orr, “SCA1 – Phosphorylation, a Regulator of Atxain-1 Function and Pathogenesis,” Prog. Neurobiol., vol. 99, no. 3, p. 179, Dec. 2012</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408849/">[PUBMED Central]</a></li>
          <li><a id="ref-six-little" class="articlebottom">S. Yue, H. G. Serra, H. Y. Zoghbi, and H. T. Orr, “The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract,” Hum. Mol. Genet., vol. 10, no. 1, pp. 25–30, Jan. 2001.</a><br><a href="https://academic.oup.com/hmg/article/10/1/25/708472?login=false">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-seven-little" class="articlebottom">E. N. Burright, J. D. Davidson, L. A. Duvick, B. Koshy, H. Y. Zognbi, and H. T. Orr, “Identification of a self-association region within the SCA1 gene product, ataxin-1,” Hum. Mol. Genet., vol. 6, no. 4, pp. 513–518, Apr. 1997.</a><br><a href="https://academic.oup.com/hmg/article/6/4/513/2901185?login=false">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-eight-little" class="articlebottom">S. Irwin et al., “RNA association and nucleocytoplasmic shuttling by ataxin-1,” J. Cell Sci., vol. 118, no. Pt 1, pp. 233–242, Jan. 2005.</a><br><a href="https://journals.biologists.com/jcs/article/118/1/233/28227/RNA-association-and-nucleocytoplasmic-shuttling-by">[Journal of Cell Science]</a></li>
          <li><a id="ref-nine-little" class="articlebottom">P. Opal and H. T. Orr, “Animal Models of Spinocerebellar Ataxia Type 1,” Mov. Disord. Genet. Model. Second Ed., pp. 979–990, Jan. 2015.</a><br><a href="https://www.sciencedirect.com/science/article/pii/B9780124051959000639">[ScienceDirect]</a></li>
          <li><a id="ref-ten-little" class="articlebottom">A. Servadio, B. Koshy, D. Armstrong, B. Antalffy, H. T. Orr, and H. Y. Zoghbi, “Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals,” Nat. Genet., vol. 10, no. 1, pp. 94–98, 1995.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7647801/">[PUBMED]</a><a href="https://www.nature.com/articles/ng0595-94">[Nature]</a></li>
          <li><a id="ref-eleven-little" class="articlebottom">H. L. Paulson, V. G. Shakkottai, H. B. Clark, and H. T. Orr, “Polyglutamine spinocerebellar ataxias — from genes to potential treatments,” Nat. Rev. Neurosci., vol. 18, no. 10, p. 613, Sep. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420820/">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-twelve-little" class="articlebottom">I. A. Klement et al., “Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice,” Cell, vol. 95, no. 1, pp. 41–53, Oct. 1998.</a><br><a href="https://www.cell.com/cell/fulltext/S0092-8674(00)81781-X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS009286740081781X%3Fshowall%3Dtrue">[Cell - Full Text]</a></li>
          <li><a id="ref-thirteen-little" class="articlebottom">H. Y. Zoghbi and H. T. Orr, “Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1,” J. Biol. Chem., vol. 284, no. 12, pp. 7425–7429, Mar. 2009.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658037/">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-fourteen-little" class="articlebottom">C. Nóbrega and L. Pereira de Almeida, Eds., Polyglutamine Disorders, vol. 1049 pp. 136-144</a><br><a href="https://link.springer.com/book/10.1007/978-3-319-71779-1">[Book]</a></li>
          <li><a id="ref-fifteen-little" class="articlebottom">B. E. Riley, H. Y. Zoghbi, and H. T. Orr, “SUMOylation of the Polyglutamine Repeat Protein, Ataxin-1, Is Dependent on a Functional Nuclear Localization Signal,” J. Biol. Chem., vol. 280, no. 23, pp. 21942–21948, Jun. 2005.</a><br><a href="https://www.jbc.org/article/S0021-9258(20)69137-2/fulltext">[JBC- Full Text]</a></li>
          <li><a id="ref-sixteen-little" class="articlebottom">Y. C. Lam et al., “ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology,” Cell, vol. 127, no. 7, pp. 1335–1347, Dec. 2006.</a><br><a href="https://www.cell.com/cell/fulltext/S0092-8674(06)01543-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867406015431%3Fshowall%3Dtrue">[Cell - Full Text]</a></li>
          <li><a id="ref-seventeen-little" class="articlebottom">M. W. C. Rousseaux et al., “ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism,” Neuron, vol. 97, no. 6, p. 1235, Mar. 2018</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422678/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-eighteen-little" class="articlebottom">U. Rüb et al., “Spinocerebellar ataxia type 1 (SCA1): new pathoanatomical and clinico-pathological insights,” Neuropathol. Appl. Neurobiol., vol. 38, no. 7, pp. 665–680, Dec. 2012.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/22309224/" class="links">[PUBMED]</a><a href="https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2990.2012.01259.x" class="links">[Wiley Online Library]</a></li>
        </ol>
      </div>
    </section>
    </div>
    <div class="aside-bar-right" id="bar-right">
      <div class="ref-side-bar">
        <h3><i class="fa-solid fa-link"></i> References</h3>
        <ul>
          <li><a href="" id="ref-one" class="articlefocus">1. &nbsp H. T. Orr and H. Y. Zoghbi, “SCA1 molecular genetics: a history of a 13 year collaboration against glutamines,” Hum. Mol. Genet., vol. 10, no. 20, pp. 2307–2311, Oct. 2001.</a><br><a href="https://academic.oup.com/hmg/article/10/20/2307/559359" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-two" class="articlefocus">2. &nbsp P. Opal and T. Ashizawa, “Spinocerebellar Ataxia Type 1,” GeneReviews®, Jun. 2017, Accessed: Mar. 07, 2022. [Online]. Available:</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK1184/" class="links">[NCBI Books]</a></li>
          <li><a href="" id="ref-three" class="articlefocus">3. &nbsp S. Banfi et al., “Identification and characterization of the gene causing type 1 spinocerebellar ataxia,” Nat. Genet. 1994 74, vol. 7, no. 4, pp. 513–520, 1994</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7951322/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/ng0894-513" class="links">[Nature]</a></li>
          <li><a href="" id="ref-four" class="articlefocus">4. &nbsp S. Nethisinghe et al., “PolyQ tract toxicity in SCA1 is length dependent in the absence of CAG repeat interruption,” Front. Cell. Neurosci., vol. 12, p. 200, Jul. 2018.</a><br><a href="https://www.frontiersin.org/articles/10.3389/fncel.2018.00200/full" class="links">[Frontiers - Full Text]</a></li>
          <li><a href="" id="ref-five" class="articlefocus">5. &nbsp H. T. Orr, “SCA1 – Phosphorylation, a Regulator of Atxain-1 Function and Pathogenesis,” Prog. Neurobiol., vol. 99, no. 3, p. 179, Dec. 2012</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408849/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-six" class="articlefocus">6. &nbsp S. Yue, H. G. Serra, H. Y. Zoghbi, and H. T. Orr, “The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract,” Hum. Mol. Genet., vol. 10, no. 1, pp. 25–30, Jan. 2001.</a><br><a href="https://academic.oup.com/hmg/article/10/1/25/708472?login=false" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-seven" class="articlefocus">7. &nbsp E. N. Burright, J. D. Davidson, L. A. Duvick, B. Koshy, H. Y. Zognbi, and H. T. Orr, “Identification of a self-association region within the SCA1 gene product, ataxin-1,” Hum. Mol. Genet., vol. 6, no. 4, pp. 513–518, Apr. 1997.</a><br><a href="https://academic.oup.com/hmg/article/6/4/513/2901185?login=false" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-eight" class="articlefocus">8. &nbsp S. Irwin et al., “RNA association and nucleocytoplasmic shuttling by ataxin-1,” J. Cell Sci., vol. 118, no. Pt 1, pp. 233–242, Jan. 2005.</a><br><a href="https://journals.biologists.com/jcs/article/118/1/233/28227/RNA-association-and-nucleocytoplasmic-shuttling-by" class="links">[Journal of Cell Science - Full Text]</a></li>
          <li><a href="" id="ref-nine" class="articlefocus">9. &nbsp P. Opal and H. T. Orr, “Animal Models of Spinocerebellar Ataxia Type 1,” Mov. Disord. Genet. Model. Second Ed., pp. 979–990, Jan. 2015.</a><br><a href="https://www.sciencedirect.com/science/article/pii/B9780124051959000639" class="links">[ScienceDirect]</a></li>
          <li><a href="" id="ref-ten" class="articlefocus">10. &nbsp A. Servadio, B. Koshy, D. Armstrong, B. Antalffy, H. T. Orr, and H. Y. Zoghbi, “Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals,” Nat. Genet., vol. 10, no. 1, pp. 94–98, 1995.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/7647801/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/ng0595-94" class="links">[Nature]</a></li>
          <li><a href="" id="ref-eleven" class="articlefocus">11. &nbsp H. L. Paulson, V. G. Shakkottai, H. B. Clark, and H. T. Orr, “Polyglutamine spinocerebellar ataxias — from genes to potential treatments,” Nat. Rev. Neurosci., vol. 18, no. 10, p. 613, Sep. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420820/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-twelve" class="articlefocus">12. &nbsp I. A. Klement et al., “Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice,” Cell, vol. 95, no. 1, pp. 41–53, Oct. 1998.</a><br><a href="https://www.cell.com/cell/fulltext/S0092-8674(00)81781-X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS009286740081781X%3Fshowall%3Dtrue" class="links">[Cell - Full Text]</a></li>
          <li><a href="" id="ref-thirteen" class="articlefocus">13. &nbsp H. Y. Zoghbi and H. T. Orr, “Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1,” J. Biol. Chem., vol. 284, no. 12, pp. 7425–7429, Mar. 2009.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658037/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-fourteen" class="articlefocus">14. &nbsp C. Nóbrega and L. Pereira de Almeida, Eds., Polyglutamine Disorders, vol. 1049 pp. 136-144</a><br><a href="https://link.springer.com/book/10.1007/978-3-319-71779-1" class="links">[Book]</a></li>
          <li><a href="" id="ref-fifteen" class="articlefocus">15. &nbsp B. E. Riley, H. Y. Zoghbi, and H. T. Orr, “SUMOylation of the Polyglutamine Repeat Protein, Ataxin-1, Is Dependent on a Functional Nuclear Localization Signal,” J. Biol. Chem., vol. 280, no. 23, pp. 21942–21948, Jun. 2005.</a><br><a href="https://www.jbc.org/article/S0021-9258(20)69137-2/fulltext" class="links">[JBC- Full Text]</a></li>
          <li><a href="" id="ref-sixteen" class="articlefocus">16. &nbsp Y. C. Lam et al., “ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology,” Cell, vol. 127, no. 7, pp. 1335–1347, Dec. 2006.</a><br><a href="https://www.cell.com/cell/fulltext/S0092-8674(06)01543-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867406015431%3Fshowall%3Dtrue" class="links">[Cell - Full Text]</a></li>
          <li><a href="" id="ref-seventeen" class="articlefocus">17. &nbsp M. W. C. Rousseaux et al., “ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism,” Neuron, vol. 97, no. 6, p. 1235, Mar. 2018</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422678/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-eighteen" class="articlefocus">18. &nbsp U. Rüb et al., “Spinocerebellar ataxia type 1 (SCA1): new pathoanatomical and clinico-pathological insights,” Neuropathol. Appl. Neurobiol., vol. 38, no. 7, pp. 665–680, Dec. 2012.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/22309224/" class="links">[PUBMED]</a><a href="https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2990.2012.01259.x" class="links">[Wiley Online Library]</a></li>
        </ul>
      </div>
    </div>
  </main>
  <footer id=footer>
    <div class="collumns">
      <div class="first-third">
        <ul>
          <li><a href="../../">Landing Page</a></li>
          <li><a href="https://abcri.pt/">ABC-RI</a></li>
          <li><a href="https://abcri.pt/research-groups/clevio-nobrega/#menu">MNGT group</a></li>
          <li><a href="https://abcri.pt/news/">ABC-RI News</a></li>
        </ul>
      </div>
      <div class="second-third">
        <ul>
          <li><a href="../../authors">Authors</a></li>
          <li><a href="https://www.ualg.pt/">UAlg</a></li>
          <li><a href="https://fmcb.ualg.pt/en">UAlg - FMCB</a></li>
          <li><a href="https://fmcb.ualg.pt/en/master-biomedical-sciences">Masters degree</a></li>
        </ul>
      </div>
      <div class="third-third">
        <ul>
          <li><a href="../../contact">Contact</a></li>
          <li><a href="../../objectives">Objectives</a></li>
          <li><a href="../../appreciation">Appreciation</a></li>
        </ul>
      </div>
    </div>
    <svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="200.000000pt" height="200.000000pt" viewBox="0 0 200.000000 200.000000" preserveAspectRatio="xMidYMid meet">
<metadata>
Created by potrace 1.10, written by Peter Selinger 2001-2011
</metadata>
<g transform="translate(0.000000,200.000000) scale(0.100000,-0.100000)" fill="#3d85c6" stroke="none">
<path d="M1514 1622 c-11 -10 -31 -22 -44 -25 -38 -10 -45 -17 -84 -82 -40 -67 -44 -94 -20 -135 18 -29 101 -80 132 -80 10 0 23 -5 29 -11 6 -6 26 -14 43 -18 24 -4 38 -16 51 -40 10 -19 23 -39 28 -44 14 -14 61 19 61 43 0 12 10 25 23 30 36 15 78 65 89 107 20 79 20 89 -8 152 -25 55 -33 64 -83 90 -72 36 -185 42 -217 13z m76 -27 c-10 -12 -10 -19 -2 -27 9 -9 18 -4 37 16 14 15 28 25 33 23 4 -2 25 -12 47 -22 40 -18 75 -43 75 -54 0 -9 -67 -7 -76 2 -12 12 -44 8 -44 -5 0 -20 48 -38 81 -31 49 9 81 -33 63 -81 -7 -19 -36 -21 -65 -3 -17 9 -23 9 -26 0 -3 -8 -14 -11 -28 -7 -12 3 -26 1 -30 -5 -3 -6 -17 -8 -31 -5 -13 3 -24 2 -24 -4 0 -19 -33 -22 -57 -6 -35 22 -52 3 -23 -24 21 -20 21 -20 2 -26 -23 -8 -117 37 -126 60 -9 24 -7 74 3 74 5 0 11 -7 15 -15 9 -26 48 -17 77 18 21 24 28 28 29 15 0 -24 22 -23 38 2 7 11 21 20 31 20 11 0 22 4 26 9 10 17 -15 23 -68 16 -38 -6 -58 -15 -78 -37 -25 -26 -29 -27 -37 -11 -19 32 20 83 64 83 8 0 23 9 34 20 11 11 32 20 46 20 23 0 25 -2 14 -15z m179 -224 l34 -1 -23 -25 c-25 -26 -59 -32 -91 -15 -15 8 -24 6 -41 -10 -13 -11 -35 -20 -54 -20 -60 0 -53 30 11 50 22 7 46 15 53 19 8 3 28 5 45 5 18 -1 47 -2 66 -3z m-34 -81 c-3 -5 -12 -10 -20 -10 -8 0 -17 5 -20 10 -4 6 5 10 20 10 15 0 24 -4 20 -10z m-61 -22 c14 -55 0 -64 -26 -19 -12 22 -13 31 -5 35 21 8 25 6 31 -16z"/>
<path d="M72 1198 c-23 -23 -14 -59 18 -71 l30 -11 0 -163 c0 -150 -1 -163 -18 -163 -37 0 -57 -51 -30 -78 15 -15 100 -15 152 -1 60 16 158 119 182 189 32 94 68 153 113 187 23 18 48 33 54 33 9 0 12 -46 12 -165 0 -91 -1 -165 -2 -165 -1 0 -13 5 -27 11 -25 12 -25 14 -28 142 l-3 130 -29 -41 c-25 -37 -28 -48 -24 -102 4 -63 -4 -78 -19 -34 -9 26 -10 26 -36 -27 l-26 -54 31 -33 c81 -83 206 -106 306 -56 81 40 129 104 177 238 20 54 73 119 117 142 l28 15 0 -166 0 -165 -22 11 c-22 10 -23 13 -20 139 3 142 -1 151 -48 88 -19 -26 -22 -40 -18 -94 2 -35 3 -64 1 -64 -1 0 -8 12 -16 26 l-14 26 -26 -53 -26 -54 32 -34 c92 -97 257 -108 353 -24 44 39 93 115 114 177 27 82 69 140 120 166 l40 20 0 -164 0 -165 -22 8 c-22 8 -23 15 -28 137 l-5 128 -29 -34 c-26 -31 -28 -39 -24 -97 4 -66 -4 -82 -19 -37 -9 26 -10 26 -36 -27 l-26 -54 32 -33 c52 -55 116 -82 191 -82 56 0 67 3 76 21 9 16 8 26 -5 45 -8 13 -22 24 -30 24 -13 0 -15 26 -15 164 0 152 1 164 19 169 31 8 43 40 25 65 -13 18 -25 22 -72 22 -131 0 -232 -90 -286 -256 -19 -57 -73 -127 -117 -149 -15 -8 -30 -15 -34 -15 -3 0 -5 74 -5 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -22 19 -143 l0 -132 28 28 c23 24 28 37 32 105 6 73 6 75 18 48 l13 -30 25 54 25 53 -38 39 c-54 55 -107 78 -181 78 -112 0 -206 -69 -259 -188 -13 -31 -34 -78 -45 -104 -21 -48 -51 -82 -100 -113 l-28 -17 0 166 c0 164 0 167 20 156 18 -10 20 -21 20 -143 l1 -132 36 39 c35 38 35 39 29 102 -7 69 -2 81 15 37 l11 -28 23 45 c32 61 31 73 -12 110 -114 100 -276 92 -375 -18 -42 -47 -63 -83 -89 -159 -10 -30 -28 -67 -40 -84 -22 -31 -94 -89 -111 -89 -4 0 -8 74 -8 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -23 19 -143 l1 -132 29 34 c25 30 30 44 32 105 3 68 4 70 17 44 l14 -27 23 50 c22 46 22 52 8 74 -17 27 -76 69 -117 84 -38 15 -140 14 -155 -1z m153 -22 c19 -8 51 -27 70 -42 50 -38 44 -69 -17 -88 -15 -4 -18 -17 -18 -71 0 -37 -4 -64 -9 -61 -5 3 -9 41 -9 83 0 43 -1 86 -1 95 -1 25 -58 53 -77 37 -19 -15 -21 -318 -2 -337 24 -24 57 -12 107 36 37 36 56 66 81 130 18 46 46 101 62 123 36 49 111 106 117 87 2 -7 10 -21 19 -30 14 -16 13 -18 -6 -18 -48 0 -103 -73 -151 -199 -26 -69 -84 -143 -133 -171 -48 -27 -161 -40 -173 -20 -5 9 3 22 24 39 l31 26 0 160 0 160 -31 26 c-19 15 -29 31 -25 37 10 17 100 15 141 -2z m487 -12 c18 -9 47 -30 65 -47 26 -24 30 -34 22 -49 -5 -10 -21 -18 -34 -18 -27 0 -33 -13 -38 -95 -2 -27 -4 -8 -5 44 -2 82 -5 98 -24 118 -25 27 -41 29 -62 7 -23 -23 -23 -315 0 -338 20 -20 20 -20 69 8 51 30 85 78 124 174 37 92 62 129 115 168 54 41 108 58 162 50 86 -11 172 -74 159 -116 -4 -13 -13 -20 -24 -18 -10 2 -25 -3 -34 -11 -15 -12 -17 -10 -17 22 0 27 -7 41 -27 57 -32 25 -54 23 -68 -6 -10 -21 -10 -21 -28 3 -22 28 -45 24 -91 -14 -46 -38 -81 -93 -106 -164 -41 -119 -116 -192 -215 -210 -87 -16 -126 9 -70 45 25 16 25 17 25 180 l0 164 -27 20 c-18 13 -24 24 -20 36 6 15 16 17 62 12 30 -3 70 -13 87 -22z m898 10 c2 -3 -9 -16 -25 -28 -30 -23 -30 -26 -33 -127 -2 -57 -5 -106 -8 -108 -2 -2 -4 43 -4 101 0 123 -9 139 -60 118 -46 -19 -112 -99 -134 -161 -25 -72 -68 -148 -103 -181 -85 -81 -235 -83 -312 -4 -25 25 -31 39 -26 55 3 12 14 21 24 21 28 0 41 21 43 70 1 26 4 11 7 -39 6 -77 8 -86 33 -104 27 -20 28 -20 48 -2 18 16 20 32 22 159 l2 141 6 -149 c6 -178 11 -185 85 -142 52 31 95 91 121 170 49 145 154 231 269 219 22 -3 42 -7 45 -9z m-1072 -380 c20 -10 21 -13 7 -24 -8 -7 -15 -19 -15 -27 0 -11 -6 -11 -30 4 -17 10 -42 30 -56 44 -22 23 -23 29 -13 52 7 15 17 23 25 20 28 -11 44 18 46 81 1 46 3 37 7 -39 6 -91 8 -100 29 -111z m912 44 c0 -55 51 -88 80 -53 11 13 16 12 41 -8 50 -39 30 -62 -44 -51 -51 8 -102 34 -139 69 -23 21 -26 29 -16 44 6 11 19 16 29 14 11 -3 21 1 25 11 9 24 24 9 24 -26z"/>
<path d="M470 550 c0 -65 3 -90 13 -90 9 0 11 23 9 90 -2 49 -8 90 -13 90 -5 0 -9 -40 -9 -90z"/>
<path d="M1090 551 l0 -89 33 1 c31 2 32 3 35 55 3 56 -10 85 -34 75 -10 -4 -14 2 -14 21 0 14 -4 26 -10 26 -6 0 -10 -36 -10 -89z m48 -27 c-2 -22 -7 -39 -13 -39 -12 0 -19 60 -10 83 10 28 27 -3 23 -44z"/>
<path d="M280 545 c0 -69 3 -85 15 -85 9 0 15 9 15 25 0 15 6 25 15 25 19 0 35 31 35 69 0 32 -22 51 -59 51 -20 0 -21 -6 -21 -85z m50 19 c0 -19 -4 -34 -10 -34 -5 0 -10 18 -10 41 0 24 4 38 10 34 6 -3 10 -22 10 -41z"/>
<path d="M612 618 c-7 -7 -12 -38 -12 -70 0 -45 5 -66 22 -88 21 -29 58 -41 58 -20 0 6 -7 10 -17 10 -15 0 -15 1 0 18 12 13 17 37 17 78 0 61 -11 84 -40 84 -9 0 -21 -5 -28 -12z m46 -85 c-5 -72 -28 -68 -28 5 0 32 3 62 7 66 13 13 24 -24 21 -71z"/>
<path d="M750 545 c0 -83 0 -85 24 -85 39 0 56 25 56 84 0 58 -19 86 -58 86 -21 0 -22 -4 -22 -85z m45 0 c0 -38 -4 -60 -12 -62 -10 -4 -13 13 -13 62 0 49 3 66 13 63 8 -3 12 -25 12 -63z"/>
<path d="M939 608 c-3 -53 3 -134 11 -142 5 -5 17 -5 27 -1 17 8 17 8 1 12 -25 6 -26 91 -2 100 15 6 15 7 -1 19 -9 7 -14 17 -10 23 3 6 -1 11 -9 11 -10 0 -17 -9 -17 -22z"/>
<path d="M392 591 c-19 -11 -27 -83 -13 -110 15 -26 47 -27 61 -2 15 29 12 87 -6 105 -18 18 -24 19 -42 7z m28 -61 c0 -27 -4 -50 -10 -50 -5 0 -10 23 -10 50 0 28 5 50 10 50 6 0 10 -22 10 -50z"/>
<path d="M510 588 c0 -7 7 -40 15 -73 12 -52 12 -61 0 -71 -20 -15 -19 -24 5 -24 19 0 28 22 45 110 4 19 9 43 11 53 4 11 0 17 -10 17 -11 0 -16 -9 -16 -29 0 -16 -3 -38 -7 -48 -6 -13 -9 -6 -13 26 -3 25 -11 46 -17 49 -7 2 -13 -2 -13 -10z"/>
<path d="M852 588 c-13 -13 -16 -38 -6 -38 4 0 13 8 20 18 12 16 13 16 20 -2 5 -13 3 -21 -4 -24 -24 -8 -43 -35 -40 -56 2 -16 11 -21 36 -23 l32 -1 0 63 c0 48 -4 64 -16 69 -22 8 -28 8 -42 -6z m38 -88 c0 -19 -11 -26 -23 -14 -8 8 3 34 14 34 5 0 9 -9 9 -20z"/>
<path d="M1006 584 c-20 -20 -20 -34 -1 -34 8 0 15 7 15 15 0 8 5 15 10 15 19 0 10 -31 -16 -54 -37 -31 -26 -66 20 -66 l33 0 -4 58 c-3 31 -6 63 -8 70 -6 17 -30 15 -49 -4z m34 -84 c0 -11 -4 -20 -10 -20 -5 0 -10 9 -10 20 0 11 5 20 10 20 6 0 10 -9 10 -20z"/>
<path d="M1193 593 c-13 -5 -18 -43 -7 -43 4 0 13 8 20 18 12 16 13 16 14 0 0 -9 -11 -29 -25 -42 -33 -33 -21 -65 25 -64 30 1 30 2 30 58 0 69 -16 90 -57 73z m23 -110 c-11 -11 -19 6 -11 24 8 17 8 17 12 0 3 -10 2 -21 -1 -24z"/>
<path d="M1271 581 c-8 -15 -5 -27 15 -56 25 -37 26 -65 0 -30 -9 13 -15 15 -20 6 -11 -17 14 -42 38 -39 29 4 32 35 7 69 -12 15 -21 34 -21 41 1 8 5 7 14 -4 17 -23 26 -23 26 1 0 17 -18 31 -40 31 -5 0 -14 -9 -19 -19z"/>
<path d="M1362 588 c-7 -7 -12 -36 -12 -65 0 -57 17 -76 48 -56 22 13 27 33 8 33 -9 0 -16 -4 -16 -10 0 -5 -4 -10 -10 -10 -5 0 -10 9 -10 20 0 15 7 20 25 20 21 0 25 5 25 28 0 29 -16 52 -35 52 -6 0 -16 -5 -23 -12z m38 -40 c0 -5 -7 -8 -15 -8 -15 0 -20 21 -8 33 7 7 23 -11 23 -25z"/>
</g>
</svg>
    <p>&copyPolyQ Database. All rights reserved 2021-2022. Authors and database creators all duly mentioned.</p>
    <div class="logos">
      <a class="logo-one"> <img src="../../Images/Logo_ABCRI.png" alt=""></a>
      <a class="logo-two"> <img src="../../Images/Logo_MNGT.png" alt=""></a>
      <a class="logo-three"> <img src="../../Images/fmcb-mod.png" alt=""></a>
    </div>
  </footer>
  <script src="../../Scripts/jquery-3.6.0.min.js"></script>
  <script src="../../Scripts/interactive-image.min.js"></script>
  <script src="../../Scripts/Image-Int-Scripts/image-int-sca1.js"></script>
  <script>
            var indicator = document.getElementById('indicator');

            var spy = new ScrollSpy(
                {
                    contexts_class: 'scrollspy'
                }
            );

            spy.Indicator({
                element: indicator
            });
</script>
<script>
/* When the user clicks on the button,
toggle between hiding and showing the dropdown content */
function myFunction() {
  document.getElementById("myDropdown").classList.toggle("show");
}

function myFunctionLittle() {
  document.getElementById("myDropdownLittle").classList.toggle("show");
}

// Close the dropdown if the user clicks outside of it
window.onclick = function(event) {
  if (!event.target.matches('.dropbtn')) {
    var dropdowns = document.getElementsByClassName("dropdown-content");
    var i;
    for (i = 0; i < dropdowns.length; i++) {
      var openDropdown = dropdowns[i];
      if (openDropdown.classList.contains('show')) {
        openDropdown.classList.remove('show');
      }
    }
  }
  if (!event.target.matches('.dropbtn-little')){
    var dropLittle = document.getElementsByClassName("dropdown-content-little");
    var r;
    for (r = 0; r < dropLittle.length; r++) {
      var openDropLittle = dropLittle[r];
      if (openDropLittle.classList.contains('show')) {
        openDropLittle.classList.remove('show');
      }
    }
  }
}

</script>
<script>


$(document).scroll(function() {
    checkOffset();
});

function checkOffset() {
    if($('#bar-right').offset().top + $('#bar-right').height() >= $('#references').offset().top + 200)
          $('#bar-right').hide(800);
    if($(document).scrollTop() + window.innerHeight < $('#references').offset().top + 200)
          $('#bar-right').show(800); // restore when you scroll up
}
</script>

<script>

function reload(){
  var imageInt = document.getElementById("my-interactive-image");
  var imageContent = imageInt.innerHTML;
  imageInt.innerHTML = imageContent;
}

// function reloadImage(reload){
//   window.location.hash = "my-interactive-image";
//   window.location.reload(true);
// }

</script>

</body>


</html>
